SCHEMBL623686

SCHEMBL623686

CC(C)COc1cc(N2CCN(C(=O)c3cnn(-c4ccccn4)c3)CC2)ncn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
HPGD P15428 1/20 0.46
ALDH1A1 P00352 6/20 0.45
MAPK1 P28482 2/20 0.45
SLC6A7 Q99884 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALKBH2 Q6NS38 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622742 0.89 CFTR (0.41) KDM4EALDH1A1SLC6A7LMNAMAPT
SCHEMBL623166 0.85 KMT2A (0.45) CDK5CDK5R1ALDH1A1L3MBTL1LMNA
SCHEMBL623256 0.82 LMNA (0.46) KDM4EALDH1A1MAPK1LMNACYP1A2
SCHEMBL624250 0.81 KDM4E (0.59) KDM4EHPGDALDH1A1LMNACYP1A2
SCHEMBL624185 0.79 KDM4E (0.44) KDM4EALDH1A1MAPK1SLC6A7L3MBTL1
SCHEMBL624539 0.78 MGLL (0.44) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL623690 0.77 POLB (0.51) KDM4EALDH1A1MAPK1SLC6A7L3MBTL1
SCHEMBL624025 0.77 ALDH1A1 (0.42) KDM4EHPGDALDH1A1MAPK1LMNA
SCHEMBL623165 0.76 CCKAR (0.44) ALDH1A1MEN1KMT2APOLBTSHR
SCHEMBL624214 0.76 PRLHR (0.40) KDM4EHPGDALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G KDM4E 1537/4885CDK5 1568/4885CDK5R1 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.